We are live on ! Find out more
NAUT icon

Nautilus Biotechnolgy
NAUT

86 hedge funds and large institutions have $120M invested in Nautilus Biotechnolgy in 2022 Q3 according to their latest regulatory filings, with 11 funds opening new positions, 20 increasing their positions, 23 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

38% more first-time investments, than exits

New positions opened: 11 | Existing positions closed: 8

4% more funds holding

Funds holding: 83 → 86 (+3)

0% more funds holding in top 10

Funds holding in top 10: 4 → 4 (0)

0.92% less ownership

Funds ownership: 46.2% → 45.28% (-0.92%)

13% less repeat investments, than reductions

Existing positions increased: 20 | Existing positions reduced: 23

23% less capital invested

Capital invested by funds: $155M → $120M (-$35M)

Holders
86
Holders Change
+3
Holders Change %
+3.61%
% of All Funds
1.48%
Holding in Top 10
4
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.07%
New
11
Increased
20
Reduced
23
Closed
8
Calls
$9K
Puts
–
Net Calls
+$9K
Net Calls Change
-$26K

Top Buyers

Rank Fund Capital Flow
1
Morgan Stanley
Morgan Stanley
New York
+$448K
2
BM
Bridger Management
New York
+$314K
3
State Street
State Street
Massachusetts
+$181K
4
GCP
GSA Capital Partners
United Kingdom
+$108K
5
SGM
Skye Global Management
Florida
+$81.7K

Top Sellers

Rank Fund Capital Flow
1
RI
RTW Investments
New York
-$1.26M
2
CAM
Crown Advisors Management
California
-$672K
3
ABG
Ally Bridge Group
New York
-$645K
4
NCM
Nantahala Capital Management
Connecticut
-$326K
5
Millennium Management
Millennium Management
New York
-$303K
Name Holding Trade Value Shares
Change 		Change in
Stake
SGM
26
Skye Global Management
Florida
$483K +$81.7K +32,500 +17%
ST
27
Sentinel Trust
Texas
$456K – – –
N
28
Nuveen
North Carolina
$443K +$8.8K +3,499 +2%
HC
29
Hillman Company
Pennsylvania
$424K – – –
Charles Schwab
30
Charles Schwab
California
$270K – – –
Bank of New York Mellon
31
Bank of New York Mellon
New York
$263K +$32K +12,705 +11%
Renaissance Technologies
32
Renaissance Technologies
New York
$189K +$64.1K +25,500 +40%
Goldman Sachs
33
Goldman Sachs
New York
$158K -$8.14K -3,236 -4%
RhumbLine Advisers
34
RhumbLine Advisers
Massachusetts
$146K +$9.46K +3,763 +6%
Citadel Advisors
35
Citadel Advisors
Florida
$134K +$71.5K +28,412 +82%
LOAMU
36
Lombard Odier Asset Management (USA)
New York
$106K – – –
BJL
37
Brighton Jones LLC
Washington
$93K -$712 -283 -0.6%
Barclays
38
Barclays
United Kingdom
$92K -$933 -371 -0.8%
GCP
39
GSA Capital Partners
United Kingdom
$91K +$108K +43,030 New
Susquehanna International Group
40
Susquehanna International Group
Pennsylvania
$79K -$219K -87,047 -70%
S
41
SignatureFD
Georgia
$79K – – –
New York State Common Retirement Fund
42
New York State Common Retirement Fund
New York
$73K +$1.01K +400 +1%
Bank of America
43
Bank of America
North Carolina
$72K -$8.8K -3,500 -9%
JP Morgan Chase
44
JP Morgan Chase
New York
$71K +$5.83K +2,320 +7%
Verition Fund Management
45
Verition Fund Management
Connecticut
$59K – – –
AGM
46
Alpine Global Management
New York
$56K – – –
HF
47
HRT Financial
New York
$53K -$90.7K -36,047 -59%
VCWA
48
Vanguard Capital Wealth Advisors
Colorado
$48K -$4.28K -1,700 -7%
AIG
49
American International Group
New York
$48K +$805 +320 +1%
VOYA Investment Management
50
VOYA Investment Management
Georgia
$44K – – –
1
2
3 4

NAUT Hedge Fund Activity: Q3 2022 in Review

86 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Nautilus Biotechnolgy (NAUT) for Q3 2022, worth a combined $120M — down 23% from $155M a quarter earlier.

Buyers outnumbered sellers: 11 funds opened new NAUT positions and 8 closed out — a net gain of 3 holders — while 20 added to existing stakes and 23 trimmed.

The largest buyer was Morgan Stanley, adding an estimated $448K. The largest seller was RTW Investments, cutting an estimated $1.26M.

  • 86 institutional investors held Nautilus Biotechnolgy (NAUT) as of Q3 2022, up from 83 in Q2 2022.
  • Funds reported $120M of Nautilus Biotechnolgy stock for Q3 2022, down 23% quarter-over-quarter.
  • 11 funds opened new Nautilus Biotechnolgy positions in Q3 2022 and 8 closed out, a net change of +3 holders.
  • The largest Nautilus Biotechnolgy buyer in Q3 2022 was Morgan Stanley, an estimated $448K added.
  • The largest Nautilus Biotechnolgy seller in Q3 2022 was RTW Investments, an estimated $1.26M sold.

Based on aggregated 13F filings for Q3 2022.